Navigation Links
Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
Date:5/15/2012

WILMINGTON, Del., May 15, 2012 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC announced today that the United States Patent and Trademark Office (USPTO) has granted Butamax Patent Number 8,178,328. The '328 patent covers a highly efficient engineered pathway for producing isobutanol from recombinant microorganisms at commercial scale.  These novel microorganisms have been designed using advanced biotechnology to convert sugar to isobutanol.

(Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO )

The '328 patent also protects extraction and distillation of the isobutanol, as well as steps for recovering the solids (distillers grains) produced during isobutanol fermentation.  Protection of biobutanol processes that produce these grains is key in that distillers grains provide a significant economic advantage for Butamax's customers and provide local agriculture with a high-protein animal feed.  With these added protections having priority back to 2005, the '328 patent extends Butamax's foundational patent estate to span key value drivers for commercialization.

The USPTO granted the '328 patent in view of the art cited against Butamax's '188 and '899 patents in reexamination requests filed by Gevo.  This means that the USPTO has determined that the '328 patent is novel and inventive over all of the publications referenced in reexamination of the '188 and '889 patents.

"Grant of this new patent supports the Butamax view that the USPTO will ultimately affirm the '188 and '889 patents at the conclusion of the re-examination process," said Paul Beckwith, CEO Butamax.

Butamax will add the '328 patent to its ongoing litigation against Gevo.  A decision on Butamax's request for preliminary injunction against Gevo for infringing its '889 patent is expected in the near term and trial for that lawsuit (which also includes the '188 patent) is scheduled for April 2013; subsequent trials are expected for July 2014.

About Butamax

Butamax™ Advanced Biofuels, LLC, a joint venture between BP and DuPont, was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com.

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact:
Cory Ziskind 646-277-1232


'/>"/>
SOURCE Butamax Advanced Biofuels, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Butamax™ Responds to Gevo Patent Infringement Lawsuit
2. Butamax™ and Fagen Announce Collaboration to Retrofit Ethanol Plants for Biobutanol Production
3. MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process
4. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
5. ScinoPharm Granted US Patent for Novel Crystal Forms
6. BioLife Solutions Granted European Biopreservation Patent
7. GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform
8. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
9. Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
10. Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
11. VIASPACE Granted US Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... ... The Center for Excellence in Education Sponsors Teacher Training Program , Bite of ... 2016 – The Center for Excellence in Education (CEE) will sponsor a Bite ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... that Edward Lanphier , Sangamo,s president and chief ... of Sangamo,s ZFP Therapeutic ® development programs and ... pm ET on Thursday, February 11, 2016, at the ... The conference is being held in New ...
(Date:2/4/2016)... 2016  CytoSorbents Corporation (NASDAQ: CTSO ), ... CytoSorb® blood filter to treat deadly inflammation in ... announced that CEO Dr. Phillip Chan , ... Group,s 2016 Disruptive Growth & Healthcare Conference, providing ... Conference Presentation Details: Where: Convene Conference ...
Breaking Biology Technology:
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., a ... simplifies the use and access of ubiquitous on-premise ... partnership with American Cyber.  ... experience leading transformational C4ISR and Cyber initiatives in ... the latest proven technology solutions," said Steve ...
(Date:1/11/2016)...  higi, the leading retail and omni-channel community engagement ... and mobile, today announced it has closed funding ... --> --> ... higi,s health platform – its network of health ... expanding services and programs to retail partners and ...
(Date:1/7/2016)... 2016  A United States District Court in ... the country to interpret a biometric privacy statute in ... against the photo website Shutterfly brought by the law firm ... vs. SHUTTERFLY, INC.; and THISLIFE, INC ( N.D. ... violates the Illinois Biometric Privacy Act by collecting and ...
Breaking Biology News(10 mins):